

13th ANNUAL CALIFORNIA CANCER CONSORTIUM CONFERENCE

“Recent Advances and New Directions in Cancer Therapy”



August 18-20, 2017

**The Langham Hotel
Pasadena, CA**

Presented by the California Cancer Consortium

University of California Davis Comprehensive Cancer Center
SACRAMENTO, CA

City of Hope Comprehensive Cancer Center
DUARTE, CA

University of Southern California/Norris Comprehensive Cancer Center
LOS ANGELES, CA

Stanford Cancer Institute Comprehensive Cancer Center
STANFORD, CA

Conference Chairs:

Primo Lara, Jr., M.D. | Edward Newman, Ph.D.

Educational Steering Committee:

David Gandara, M.D.

Shivaani Kummar, M.D.

Heinz-Josef Lenz, M.D.

**Sponsored by:
THE MEDICAL EDUCATOR
CONSORTIUM**



PROGRAM CHAIRS

Primo Lara, Jr., M.D.

Acting Director, UCD Comprehensive Cancer Center

Professor of Medicine

University of California Davis School of Medicine

Associate Director for Translational Research
University of California Davis Comprehensive Cancer Center

Edward Newman, Ph.D.

Associate Professor, Cancer Biology

Co-Leader of the Development Cancer Therapeutics Program

City of Hope Comprehensive Cancer Center
Duarte, CA

STEERING COMMITTEE

David Gandara, M.D.

Professor of Medicine

University of California Davis School of Medicine

Senior Advisor to the Director, University of California Davis Comprehensive Cancer Center

Shivaani Kummur, M.D.

Professor of Medicine

Stanford University School of Medicine

Heinz-Josef Lenz, M.D.

Professor of Medicine and Preventive

Medicine, Section Head of GI Oncology
University of Southern California,
Keck School of Medicine

Associate Director for Clinical Research,
University of Southern California Norris
Comprehensive Cancer Center

DISTINGUISHED FACULTY

Afsaneh Barzi, MD, PhD

Assistant Professor of Medical Oncology

Department of Medicine

Division of Oncology

USC Norris Comprehensive Cancer Center
Los Angeles, CA

Robert Chen, MD

Associate Professor

City of Hope Medical Center

Duarte, CA

Helen Chew, MD

Professor of Medicine, Division of

Hematology/Oncology

UC Davis Comprehensive Cancer Center

Sacramento, CA

Vincent Chung, MD, FACP

Associate Clinical Professor

City of Hope Department of Medical Oncology

Duarte, CA

A. Dimitrios Colevas, MD

Associate Professor of Medicine

Stanford University School of Medicine

Stanford, CA

Mihaela Cristea, MD

Assistant Professor, Department of Medical

Oncology and Therapeutics Research

City of Hope Comprehensive Cancer Center

Duarte, CA

Tanya Dorff, MD

Assistant Professor

USC Keck School of Medicine

Norris Comprehensive Cancer Center

Los Angeles, CA

Oliver Dorigo, MD, PhD

Professor

Stanford University School of Medicine

Stanford, CA

Anthony El-Khoueiry, MD

Assistant Professor

USC California Keck School of Medicine

Norris Comprehensive Cancer Center

Los Angeles, CA

Marwan Fakih, MD

Interim Chair and Professor, Medical

Oncology and Therapeutics Research

Section Head, GI Medical Oncology

Co-Director, GI Cancers Program

City of Hope Comprehensive Cancer Center

Duarte, CA

Paul Frankel, PhD

Staff Scientist, Division of Biostatistics

Department of Information Sciences

Beckman Research Institute, City of Hope

Comprehensive Cancer Center

Duarte, CA

David Gandara, MD

Professor of Medicine

Division of Hematology and Oncology

UC Davis Comprehensive Cancer Center

Sacramento, CA

Susan Groshen, PhD

Professor of Medicine and Director

Biostatistics Core

USC Norris Comprehensive Cancer Center

Los Angeles, CA

James Hu, MD

USC Norris Comprehensive Cancer Center

Hematology/Oncology Services

Los Angeles, CA

Brian Jonas, MD, PhD

Assistant Professor, Division of

Hematology/Oncology

UC Davis School of Medicine

Sacramento, CA

Kevin Kelly, MD, PhD

Associate Professor of Clinical Medicine

Assistant Medical Director of Clinical

Investigations Support Office, Jane Anne Nohl

Division of Hematology and Center for the

Study of Blood Diseases

University of Southern California

Los Angeles, CA

Edward Kim, MD, PhD

Assistant Professor Division of

Hematology and Oncology

UC Davis Comprehensive Cancer Center

Sacramento, CA

Mariana Koczywas, MD

Clinical Professor of Medicine

City of Hope Comprehensive Cancer Center

Duarte, CA

Shivaani Kumar, MD
Professor, Department of Medicine
Director, Phase I Clinical Research Program
Stanford University School of Medicine
Stanford, CA

Primo Lara, Jr., MD
Professor of Medicine, Associate Director for
Translational Research
UC Davis Comprehensive Cancer Center
Sacramento, CA

Peter Lee, MD
Billy Wilder Endowed Professor
Chair, Department of Immuno-Oncology
City of Hope Comprehensive Cancer Center
Duarte, CA

Heinz-Josef Lenz, MD, PhD
Professor of Medicine and Preventive Medicine
Section Head of GI Oncology
University of Southern California
Keck School of Medicine
Associate Director for Clinical Research
USC Norris Comprehensive Cancer Center
Los Angeles, CA

Jeffrey Longmate, PhD
Professor and Director, Division of Biostatistics
Department of Information Sciences
Beckman Research Institute
City of Hope Comprehensive Cancer Center
Duarte, CA

Philip Mack, PhD
Associate Professor of Medicine, UC Davis
School of Medicine
Director, Cancer Molecular Pharmacology
UC Davis Comprehensive Cancer Center
Sacramento, CA

Guido Marcucci, MD
Professor of Medicine, Department of Medical
Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, CA

Kim Margolin, MD
Professor of Medicine, Department of Medical
Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, CA

Erminia Massarelli, MD, PhD
Associate Clinical Professor
Department of Medical Oncology &
Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, CA

Arta Monjazeb, MD, PhD
Associate Professor
Department of Radiology Oncology
City of Hope Comprehensive Cancer Center
Duarte, CA

Edward Newman, PhD
Associate Professor, Molecular Pharmacology
Co-director, Analytical Pharmacology Core Facility
City of Hope Comprehensive Cancer Center
Duarte, CA

Sumanta Pal, MD
Assistant Professor, Department of Medical
Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, CA

Mamta Parikh, MD, MS
Assistant Professor
Hematology & Oncology
UC Davis Comprehensive Cancer Center
Sacramento, CA

Mark Pegram, MD
Professor of Medicine
Director of the Breast Cancer Program
Co-Director of Molecular Therapeutic
Program Stanford University
Stanford, CA

Christiane Querfeld, MD, PhD, FAAD
Chief, Division of Dermatology
Director, Cutaneous Lymphoma Program
Assistant Professor/Dermatology/
Dermatopathology
City of Hope Comprehensive Cancer Center
Duarte, CA

David Quinn, MBBS, PhD
Associate Professor and Head
Section of GU Medical Oncology
USC Keck School of Medicine Leader
Developmental Therapeutics Program
USC Norris Comprehensive Cancer Center
Los Angeles, CA

Sunil Reddy, MD
Clinical Assistant Professor
Medicine-Oncology
Stanford Cancer Center
Stanford, CA

Jonathan Riess, MD
Assistant Professor
UC Davis School of Medicine
Sacramento, CA

Sarmad Sadeghi, MD, PhD
Assistant Professor, University of
Southern California
Division of Oncology
Norris Comprehensive Cancer Center
Los Angeles, CA

Ravi Salgia, MD, PhD
Professor, Department of Medical Oncology
and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, CA

Sandy Srinivas, MD
Associate Professor
Stanford University School of Medicine
Stanford, CA

Joseph Tuscano, MD
Professor of Medicine, Division of Hematology
and Oncology, UC Davis School of Medicine
UC Davis Comprehensive Cancer Center
Sacramento, CA

Przemyslaw Twardowski, MD
Associate Professor, Department of Medical
Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, CA

Jeff Weitzel, MD
Professor of Oncology & Population Sciences
Chief, Division of Clinical Cancer Genomics
City of Hope Comprehensive Cancer Center
Duarte, CA

Yuan Yuan, MD, PhD
Assistant Professor
Department of Medical Oncology &
Therapeutic Research
City of Hope Comprehensive Cancer Center
Duarte, CA

“Recent Advances and New Directions in Cancer Therapy”

COURSE DESCRIPTION

This conference aims to provide up-to-date information to the clinician regarding new advances in cancer biology, diagnosis, and treatment. It will bring together respected opinion leaders, practicing clinicians and scientists engaged in clinical cancer research to discuss the latest cancer diagnostic and therapeutic advances. Topics focus on the major cancers and drug development areas, including signal transduction/CDK inhibition, angiogenesis inhibition, PI3K/mTOR inhibition, antibody-drug conjugates, and immunotherapy, among others. This annual conference also includes interactive roundtable discussion forums with participation of cancer care experts from the California Cancer Consortium, and features renowned professionals from academia, patient advocacy, government, payer, industry, and business realms of cancer care.

EDUCATIONAL OBJECTIVES

After participating in this educational activity, you should be able to:

- Identify signaling and immunotherapeutic pathways that are involved in the growth and metastases of various tumor types, and identify specific opportunities for therapeutic intervention.
- Describe recent advances in the molecular phenotyping of cancer and relate these to the optimal management of patients with cancer.
- Based on recent clinical trials, assess the efficacy of novel therapeutic strategies in the treatment of patients with cancer.
- Discuss new and emerging clinical trial designs that can test and validate new therapeutic strategies for cancer patients.

TARGET AUDIENCE

This program will be of interest to medical oncologists, hematologists, surgical oncologists, radiation oncologists, diagnostic radiologists, pulmonologists, urologists, gastroenterologists, pathologists, fellow and resident trainees, advanced care practitioners, registered nurses, physician assistants, clinical research coordinators, biostatisticians, and others involved in oncologic drug development and clinical care.

NEEDS ASSESSMENT

This course was developed in cooperation with the academic faculty and scientists belonging to the California Cancer Consortium to provide an annual in-depth exposure and review of new advances in cancer drug development, biology, biomarkers, diagnosis, and therapy. The agenda and format was specifically designed to address knowledge gaps identified from prior course participant evaluations and unsolicited comments from practicing oncologists (from private practice, academia) as well as scientists involved in cancer clinical trials. This area of knowledge will be best addressed by an in-depth conference on systemic therapy of malignancies (both solid and hematologic), with ample time provided for interaction by attendees with expert faculty. It is expected that this course will enhance the clinical competence of clinicians in managing the care of the cancer patient, and subsequently, improve patient outcomes.

ACCREDITATION

The Medical Educator Consortium is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Medical Educator Consortium designates this live educational activity for a maximum of 13.5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

DISCLOSURE

The Medical Educator Consortium (MEC) adheres to the ACCME Standards for Commercial Support. All persons that will be in a position to control the content of the CME Activity are required to disclose all relevant financial relationships. Faculty disclosure forms outlining this information will be made available to all participants prior to educational Activity. MEC has also implemented a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.

NURSING CONTINUING MEDICAL EDUCATION

Continuing Medical Education is acceptable for meeting RN continuing education requirements, as long as the course is *AMA PRA Category 1 Credits*[™], and has been taken within the appropriate time frames.

CONFERENCE AGENDA

13th Annual California Cancer Consortium Conference “Recent Advances and New Directions in Cancer Therapy”

FRIDAY, AUGUST 18th, 2017

11:30 am Registration & Visit Exhibits

12:45 pm - 1:55 pm Product Showcase Lunch (Non CME)

2:00 pm Welcome and Introductions

Session 1: Everything Old is New Again: Targeting DNA Repair Pathways in Oncology *Chairs: Primo Lara (UC Davis) and Edward Newman (City of Hope)*

2:15 pm DNA Repair (PARP, Wee1, ATM, ATR, etc) as a Therapeutic Target
Jeff Weitzel, City of Hope

2:35 pm Question-and-Answer Session

2:40 pm BER Inhibitors (TRC102)
Marianna Koczywas, City of Hope

3:00 pm Question-and-Answer Session

3:05 pm ATR Inhibition (VX-970)
Sumanta Pal, City of Hope

3:25 pm Question-and-Answer Session

3:30 pm Novel Cytotoxics in Development
Sarmad Sadeghi, USC

3:50 pm Question-and-Answer Session

3:55 pm – 4:25 pm Product Showcase (Non-CME)

4:25 pm – 4:40 pm Refreshment Break; Visit Exhibits

Session 2: Clinical Trial Design *Chairs: Susan Groshen (USC) and Paul Frankel (City of Hope)*

4:40 pm Design of Phase I Trials 101: Beyond Modified Fibonacci (CRM, TITE-CRM, etc)
Shivaani Kummar, Stanford

5:00 pm Question-and-Answer Session

5:05 pm Design of Phase 2 Trials 101: Promise and Pitfalls of Interim Analysis
Susan Groshen, USC

5:25 pm Question-and-Answer Session

5:30 pm Statistical Considerations for Molecular Correlative Studies in Phase I and II Trials
Jeff Longmate, City of Hope

5:50 pm Question-and-Answer Session

5:55 pm Roundtable Discussion
Moderator: Edward Newman (City of Hope)
Participants: Jeff Longmate, Paul Frankel, Susan Groshen, Shivaani Kummar

6:15 pm Adjourn for the Day

6:30 pm – 7:30 pm Welcome Reception

7:30 pm – 9:00 pm Product Showcase – Dinner (Non CME)

CONFERENCE AGENDA

SATURDAY, AUGUST 19th, 2017

6:30 am Registration, Breakfast, & Visit Exhibits

6:45 am – 7:55 am Breakfast & Product Showcase (Non-CME)

8:00 am Welcome and Introduction

Session 3: Cancer Immunotherapy

Chair: Tanya Dorff (USC) and Mamta Parikh (UC Davis)

8:05 am Overview of Immuno-Oncology

Arta Monjazeb, UC Davis

8:25 am Question-and-Answer Session

8:30 am Measuring Immune Response in Tumors

Peter Lee, City of Hope

8:50 am Question-and-Answer Session

Session 4: Malignant Melanoma

Chair: Edward Newman (City of Hope) and Christiane Querfeld (City of Hope)

8:55 am State of the Art: Immunotherapy

Kim Margolin, City of Hope

9:15 am Question-and-Answer Session

9:20 am State of the Art: Targeted Therapies (BRAF, etc)

Sunil Reddy, Stanford

9:40 am Question-and-Answer Session

9:45 am – 10:30 am Refreshment Break; Visit Exhibits

9:55 am – 10:25 am Product Showcase (Non-CME)

Session 5: Lung Cancers

Chairs: Erminia Massarelli (City of Hope) and Jonathan Riess (UC Davis)

10:30 am Evolution and Increasing Complexity of Therapeutic Decision-Making in Advanced NSCLC

David Gandara, UC Davis

10:50 am Question-and-Answer Session

10:55 am Small Cell Lung Cancer: State of the Art 2017

Ravi Salgia, City of Hope

11:15 am Question-and-Answer Session

11:20 am EGFR Inhibitors in Lung Cancer

Jonathan Riess, UC Davis

11:40 am Question-and-Answer Session

11:45 am ALK, MET, RET, NTRK Inhibitors in Lung Cancer
<TBA>

12:05 pm Question-and-Answer Session

12:10 pm Lunch Break, Product Showcase, Visit Exhibits

12:20 pm – 1:20 pm Product Showcase (Non-CME)

1:20 pm Visit Exhibits

CONFERENCE AGENDA

Session 6: Hematologic Malignancies

Chair: Guido Marcucci (City of Hope) and Joseph Tuscano (UC Davis)

- 1:30 pm** New Developments in Acute Lymphocytic Leukemia
Brian Jonas, UC Davis
- 1:50 pm** Question-and-Answer Session
- 1:55 pm** New Developments in Acute Myeloid Leukemia
Kevin Kelly, USC
- 2:15 pm** Question-and-Answer Session
- 2:20 pm** State of the Art: Malignant Lymphomas
Robert Chen, City of Hope
- 2:40 pm** Question and Answer Session
- 2:45 pm** New Developments in Plasma Cell Dyscrasias
Joseph Tuscano, UC Davis
- 3:05 pm** Question and Answer Session
- 3:10 pm – 3:20 pm** Refreshment break, Visit Exhibits

Session 7: Genitourinary Malignancies

Chairs: Mamta Parikh (UC Davis) and Samrad Sadeghi (USC)

- 3:20 pm** Castration Resistant Prostate Cancer
Przemyslaw Twardowski, City of Hope
- 3:40 pm** Question-and-Answer Session
- 3:45 pm** Renal Cell Carcinoma
Sandya Srinivas, Stanford
- 4:05 pm** Question-and-Answer Session
- 4:10 pm** Advances in Urothelial Cancer
David Quinn, USC
- 4:30 pm** Question and Answer Session

Session 8: Gastrointestinal Malignancies

Chairs: Vincent Chung (City of Hope) and Afsaneh Barzi (USC)

- 4:35 pm** New Developments in Esophagogastric and Pancreatic Cancers
Edward Kim, UC Davis
- 4:55 pm** Question-and-Answer Session
- 5:00 pm** New Developments in Colorectal Cancer
Marwan Fakih, City of Hope
- 5:20 pm** Question-and-Answer Session
- 5:25 pm** Update on Immunotherapy in GI Cancer
Anthony El-Khoueiry, USC
- 5:45 pm** Question-and-Answer Session
- 5:50 pm** Adjourn for the Day

CONFERENCE AGENDA

SUNDAY, AUGUST 20th, 2017

6:30 am Registration, Refreshments & Visit Exhibits

6:45 am – 7:55 am Breakfast & Product Showcase (Non-CME)

8:00 am Introduction

Session 9: Breast Cancer

Chair: Yuan Yuan (City of Hope) and Helen Chew (UC Davis)

8:10 am Adjuvant Therapy in Breast Cancer: State of the Art
Mark Pegram, Stanford

8:30 am Question-and-Answer Session

8:35 am Metastatic Breast Cancer
Helen Chew, UC Davis

8:55 am Question-and-Answer Session

9:00 am – 9:45 am Refreshment Break & Visit Exhibits

9:10 am – 9:40 am Product Showcase (Non-CME)

Session 10: Solid Tumors, New Therapeutics, and New Diagnostics

Chairs: Edward Newman (City of Hope) and Primo Lara (UC Davis)

9:45 am Head and Neck Cancer: New Developments
A. Dimitrios Colevas, Stanford

10:05 am Question-and-Answer Session

10:10 am Soft Tissue Sarcoma: Evolving Standards of Care
James Hu, USC

10:30 am Question-and-Answer Session

10:35 am Gynecologic Malignancies: New Approaches in 2017
Mihaela Cristea, City of Hope

10:55 am Question-and-Answer Session

11:00 am Cell Therapy for Gynecologic Cancers
Oliver Dorigo, Stanford

11:20 am Question-and-Answer Session

11:25 am Circulating Tumor DNA: Clinical Applications
Philip Mack, UC Davis

11:45 am Question-and-Answer Session

11:50 am Closing and Adjourn

HOTEL INFORMATION



THE LANGHAM HOTEL PASADENA, CA

1401 South Oak Knoll Avenue
Pasadena, CA 91106
(626) 568-3900

Reservations: 1-800-591-7481

The Langham Hotel, Pasadena has been recognized with numerous accolades and awards from some of the top luxury hotel, meetings, dining and leisure travel publications in the world. The Los Angeles' original getaway. Experience the iconic landmark hotel located in charming Pasadena, just minutes from Downtown.

Historical Property tours are offered daily at 2:00pm, led by our Service Stylists; please meet in the Lobby. Tours are also pre-reservable through our Concierge Desk at (626) 568-3900, or download a self-guided Historical Property Tour. See over 100 years of Langham Huntington history by downloading our Historic Timeline.

The Langham is offering special rates during this conference of \$219 ++ for Deluxe King accommodations. Cut off date to make reservations is July 17, 2017, after that date reservations are based on hotel availability.

FOR RESERVATION CONTACT the in-house reservation team at 1-800-591-7481 and reference the group name (California Cancer Conference) or group code (MEC081817).

CONFERENCE MANAGEMENT

MEETING EVENTS & CONFERENCE COORDINATORS, INC (MECC)

6619 South Dixie Highway, #341

Miami, FL 33143

Telephone: 305.663.1628

Fax: 305.675.2718

Website: www.meccinc.com

Email: tvalls@meccinc.com

Register online at www.meccinc.com under the conference information and registration tab.

“Recent Advances and New Directions in Cancer Therapy”

August 18-20, 2017, The Langham Hotel, Pasadena, CA

Register online at www.meccinc.com or fax to 305.675.2718

Registration Form

Name _____ Degree _____

Address _____

Telephone (____) _____ Fax (____) _____

Email Address _____

Specialty _____

TYPE OF PRACTICE:

- Private Academic
 Hospital Other

REGISTRATION FEE:

- \$175 Physician
 \$ 90 Nurse, Nurse Practitioner, Resident, Fellow,
Students, Non-physician researchers and staff
(e.g., CRAs)
 \$300 Industry Professional

Refunds must be provided in writing prior to July 8th, 2017. A \$50 administrative charge will be deducted for all refunds prior to July 8th, after July 8th no refunds will be provided.

I authorize MECC to charge my credit card i/a/o \$ _____ for the registration of this course using the following credit card.

Name as it appears on the card _____ Exp. Date _____

Card number _____ CVV Code: _____

Authorized signature _____

**For those requiring special assistance, contact MECC
at 305.663.1628 or via email tvalls@meccinc.com no later than July 8th, 2017**

Meetings, Events and Conference Coordinators, Inc.
P.O. Box 430376
Miami, FL 33243-0376

PRST STD
US Postage
PAID
Miami, FL
Permit No. 1429

13th ANNUAL CALIFORNIA CANCER CONSORTIUM CONFERENCE

“Recent Advances and New Directions in Cancer Therapy”

August 18-20, 2017

The Langham Hotel, Pasadena, CA